aTyr Pharma, Inc.ATYRNASDAQ
Loading
EV to Sales: Premium ValuationElevated
Percentile Rank92
3Y CAGR+330.7%
5Y CAGR+414.2%
Year-over-Year Change
Enterprise value to sales ratio
3Y CAGR
+330.7%/yr
Annual compound
5Y CAGR
+414.2%/yr
Recent deceleration
Percentile
P92
Near historical high
vs 5Y Ago
3595.1x
Strong expansion
Streak
1 yr
Consecutive declineElevated
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 390.04 | -66.2% |
| 2024 | 1153.42 | +377.4% |
| 2023 | 241.62 | +4847.7% |
| 2022 | 4.88 | - |
| 2021 | 0.00 | -100.0% |
| 2020 | 0.11 | -99.5% |
| 2019 | 19.73 | - |
| 2018 | 0.00 | - |
| 2017 | 0.00 | - |
| 2016 | 0.00 | - |